CANDESARTAN
Glucose Intolerance
Fundación Cardiovascular de ColombiaSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Glucose Intolerance cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DULAGLUTIDE University of Pennsylvania | Phase 4 | BBB |
Bxcl501 Pontificia Universidad Catolica de Chile | Phase 4 | BB |
NEPENTHE Washington University School of Medicine | Phase 4 | BB |
DULAGLUTIDE The University of Texas Health Science Center, Houston | Phase 4 | BB |
CYANOCOBALAMINUM The University of Texas Health Science Center, Houston | Phase 4 | BB |
View all 16 →
Same molecule, other indications
CANDESARTAN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →